Article info
PDFPostScript
Letter
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2
- Correspondence to Professor C Oliver Hanemann, Peninsula Clinical Trials Unit, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth PL6 8BU, UK; Oliver.Hanemann{at}plymouth.ac.uk
Citation
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2
Publication history
- Received September 27, 2018
- Revised January 9, 2019
- Accepted January 16, 2019
- First published February 4, 2019.
Online issue publication
September 12, 2019
Article Versions
- Previous version (12 September 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.